Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone in previously treated advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2300071458Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Jan 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of utidelone in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
utidelone
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300071458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071458.